Results 191 to 200 of about 94,936 (269)

Therapeutic outcomes of PD-1 blockade-related regimens versus docetaxel in previously immunotherapy-treated advanced non-small cell lung cancer: a retrospective, exploratory study. [PDF]

BMC Cancer
Huang TT, Wang XY, Li Q, Song PF.
europepmc   +1 more source

Metabolism in Tumor: Mechanisms and Therapeutic Perspectives

MedComm, Volume 7, Issue 9, September 2026.
Tumor metabolic reprogramming converges on three hubs—the SREBP1/2–FASN–SCD1 lipogenic axis, the HIF‐1α–GLUT1–LDHA glycolytic axis, and the LDLR–SCARB1–LXR cholesterol system—which integrate transcriptional, epigenetic (histone lactylation, m6A), and microenvironmental inputs to generate metabolic plasticity, immune evasion, and therapy resistance ...
Jia‐Chen Cheng, Yi‐Xuan Hu, Xiang‐Chun Huang, Shan Jiang, Jie‐Lin Wang, Yang Zhao, Shuo Chen   +6 more
wiley   +1 more source

Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models. [PDF]

Front Immunol
Lee JK, Fabian KP, Santiago-Sanchez GS, Rosato F, Padget MR, Lee C, Su Z, Moisan J, Katragadda M, Schlom J, Gulley JL, Bayliffe A, Hodge JW.   +12 more
europepmc   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

A Combined Chemoinformatics- and Machine Learning-Based Approach Identifies Chlormidazole as a Drug Repurposing Candidate against Aggressive Prostate Cancer. [PDF]

J Med Chem
Bernal L, Pinzi L, Martinelli T, Rinaldi A, Piccinini I, Belluti S, Bisi N, Imbriano C, Rastelli G.   +8 more
europepmc   +1 more source

Oxidative and Antioxidant Systems in Ferroptosis of Cancer: Mechanisms, Regulations, and Therapeutic Targeting

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Ferroptosis is governed by the balance between reactive oxygen species (ROS)‐driven lipid peroxidation and a multi‐tiered antioxidant network. ROS sources include mitochondrial electron transport chain, voltage‐dependent anion channels, NADPH oxidases, and endoplasmic reticulum‐resident oxidoreductases, while antioxidant defenses span the primary GSH ...
Deepak K, Pritam Kumar Roy, Maniklal Shee, Budhaditya Mukherjee, Aoife Ward Gahlawat, Mahitosh Mandal   +5 more
wiley   +1 more source

RATIONALE-303: Long-Term Outcomes of Tislelizumab in Previously Treated Advanced/Metastatic NSCLC. [PDF]

JTO Clin Res Rep
de Marchi P, Fan Y, Ma Z, Wang Y, Bao Y, Zheng W, Naicker K, Zhou C.   +7 more
europepmc   +1 more source

Nanoparticle‐Mediated Therapy for Glioma: Advances and Prospects

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Various nanocarriers, including liposomes, dendrimers, exosomes and gold nanoparticles, are designed to penetrate the blood‐brain barrier and deliver chemotherapy, radiotherapy, immunotherapy, gene therapy, phototherapy, magnetic hyperthermia and sonodynamic therapy for glioma.
Wenqian Jiang, Jing Fei, Rangrang Fan, Haifeng Chen, Liangxue Zhou, Gang Guo   +5 more
wiley   +1 more source

Long‐Term Prognosis and Immunotranscriptomic Landscape in Esophageal Squamous Cell Carcinoma With Different Pathological Responses to Neoadjuvant Chemoradiotherapy: A Retrospective Cohort Study

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This study comprehensively characterizes the long‐term prognosis and immunotranscriptomic landscape associated with different tumor regression grades (TRGs) in esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemoradiotherapy. By integrating bulk RNA‐seq, single‐cell transcriptomics, and multiplexed immunohistochemistry, we demonstrate ...
Jianye Yuan, Zelin Weng, Xinke Zhang, Fangqi Deng, Zihui Tan, Jian Zhong, Rui Chen, Xiuying Xie, Xiaodan Lin, Ting Lin, Yan Huang, Qianwen Liu, Jing Wen, Jianhua Fu   +13 more
wiley   +1 more source

Exploring the impacts of docetaxel and paclitaxel based neoadjuvant therapies on early postoperative complications in HER2-positive breast cancer patients. [PDF]

World J Surg Oncol
Sagdic MF, Tunc E, Kaya S, Kulturoglu MO, Yıldırım ÖA, Dogan L.   +5 more
europepmc   +1 more source